Short- and long-term outcomes of surgical treatment in patients with intestinal Behcet’s disease

Table 1 Patient characteristics and clinical variables

	Cases (n = 39)
Age (yr) at the time of diagnosis of BD, median (IQR)	36 (29-49)
Age (yr) at the time of diagnosis of intestinal BD, median (IQR)	38 (30-49)
Age (yr) at the time of surgery, median (IQR)	49 (31-57)
Interval (yr) between intestinal BD diagnosis and surgical treatment, median (IQR)	3 (1-8)
Sex, n (%)
Male	20 (51.3)
Female	19 (48.7)
Symptoms and signs of BD, n (%)
Oral ulcer	14 (35.9)
Genital ulcer	7 (18.0)
Ocular lesion	1 (2.6)
Skin lesion	0 (0.0)
Arthritis	0 (0.0)
Vascular lesion	1 (2.6)
Neurologic lesion	0 (0.0)
Location of ulceration, n (%)
Ileocecal	35 (89.7)
Ascending colon	3 (7.7)
Rectum	1 (2.6)
Medications, n (%)
Steroids	28 (71.8)
Colchicine	31 (79.5)
5-ASA or sulfasalazine	27 (69.2)
Azathioprine or 6-MP	23 (59.0)
TNF-α inhibitor	15 (38.5)
Antibiotics	13 (33.3)
Indication for operation, n (%)
Medical intractability	16 (41.0)
Perforation or fistula	16 (41.0)
Stricture	4 (10.3)
Bleeding	3 (7.7)
Preoperative CRP (mg/L), median (IQR)	3.9 (0.92-6.41)
Preoperative ESR (mm/h), median (IQR)	30.0 (15.0-49.5)
Preoperative neutrophil (%), median (IQR)	66.1 (59.0-73.8)
Preoperative lymphocyte (%), median (IQR)	18.1 (11.8-27.2)
Preoperative procalcitonin, median (IQR)	0.0 (0.0-0.1)
Preoperative albumin (g/dL), median (IQR)	3.0 (2.6-3.3)

BD: Behcet’s disease; IQR: Interquartile range; 5-ASA: 5-Aminosalicylic acid; 6-MP: 6-Mercaptopurine; TNF: Tumor necrosis factor; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.